

Special Issue

The Emerging Role of Metabolomics in Epidemiological Studies of Atherosclerosis and Cardiovascular Disease

Message from the Guest Editors

This Special Issue aims to extensively highlight current knowledge about newly identified metabolic markers for CVD and vascular disorders, including basic, clinical, epidemiologic and genetic findings. Here, vascular disorders include heart disease (myocardial infarction, angina, heart failure), stroke, and peripheral vascular disease. Multi-omics studies, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and gut microbiome studies, are particularly welcome. Potential topics include, but are not limited to, the following:

- Metabolites involved in the pathogenesis of CVD and vascular disorders;
- Novel proteins and related pathways involved in CVD and vascular disorders;
- The identification of lifestyle behaviors and environmental factors that modify the risks of CVD and related disorders;
- Novel findings linking early life experience to the development of CVD and vascular disorders in later life

Guest Editors


Dr. Hao Peng

Prof. Dr. Chenwei Pan

Dr. Changwei Li

Deadline for manuscript submissions

closed (20 July 2024)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/189335

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).